Why the study?
Does irbesartan prevent the progression of nephropathy in patients with nephropathy due to type 2 diabetes?
Population
Patients with nephropathy due to type 2 diabetes
Authors
Loading...
Supports irbesartan for renoprotection in type 2 diabetic nephropathy beyond BP lowering; confirms independent ARB benefit in this population.
Does irbesartan prevent the progression of nephropathy in patients with nephropathy due to type 2 diabetes?
Irbesartan provides renoprotection against the progression of diabetic nephropathy independent of its blood pressure-lowering effects.
Lewis et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: